The INK4A/ARF locus and its two gene products

Current Opinion in Genetics and Development

Volumn 9, Issue 1, 1999, Pages 22-30

  Sharpless, Norman E ^a   Depinho, Ronald A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GENE PRODUCT; PROTEIN P53;

CANCER; CELL AGING; CELL GROWTH; CELL SURVIVAL; CHROMOSOME 9P; GENE MUTATION; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033037541     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(99)80004-5     Document Type: Article

References (81)

1. Sherr CJ Cancer cell cycles. Science. 274:1996;1672-1676.
2. Levine AJ p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
3. Serrano M, Hannon GJ, Beach D A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
4. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
5. INK4b is a potential effector of cell cycle arrest mediated by TGF-β Nature. 371:1994;257-261.
6. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A Complex structure and regulation of the p16(MTS1) locus. Cancer Res. 55:1995;2988-2994.
7. INK4a transcript. Cancer Res. 55:1995;2995-2997.
8. Duro D, Bernard O, Della VV, Berger R, Larsen CJ A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene. 11:1995;21-29.
9. Quelle DE, Zindy F, Ashmun RA, Sherr CJ Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000.
10. Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N, Shimazaki C, Emi N, Takeyama K, Hirosawa Set al. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood. 87:1996;4949-4958.
11. Gardie B, Cayuela J, Martini S, Sigaux F Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood. 91:1998;1016-1020.
12. Drexler HG Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 12:1998;845-859.
13. Flores JF, Walker GJ, Glendening JM, Haluska FG, Castresana JS, Rubio MP, Pastorfide GC, Boyer LA, Kao WH, Bulyk MLet al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res. 56:1996;5023-5032.
14. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr., Tucker MA, Dracopoli NC Germline p16 mutations in familial melanoma. Nat Genet. 8:1994;15-21.
15. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus Jet al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 8:1994;23-26.
16. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr.et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 333:1995;970-974.
17. Holland EA, Beaton SC, Becker TM, Grulet OM, Peters BA, Rizos H, Kefford RF, Mann GJ Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene. 11:1995;2289-2294.
18. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJet al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA. 93:1996;8541-8545.
19. Flores JF, Pollock PM, Walker GJ, Glendening JM, Lin AH, Palmer JM, Walters MK, Hayward NK, Fountain JW Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene. 15:1997;2999-3005.
20. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De PE, Hankeln T, Meyer ZBH, Beach D A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269:1995;1281-1284.
21. INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 12:1996;97-99.
22. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8:1994;2939-2952.
23. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science. 267:1995;249-252.
24. Koh J, Enders GH, Dynlacht BD, Harlow E Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 375:1995;506-510.
25. Dyson N The regulation of E2F by pRB-family proteins. Genes Dev. 12:1998;2245-2262.
26. INK4a function by certain tumor-associated mutations.
27. •].
28. •].
29. ARF.
30. ARF is shown to act upstream of p53 as p53-null cells resist ARF-induced arrest, whereas p53-induced growth arrest in response to DNA damage is preserved in ARF null cells.
31. •].
32. •].
33. •].
34. INK4a, p53, and pRB expression in various human cell lines.
35. ••].
36. Haupt Y, Maya R, Kazaz A, Oren M Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299. MDM2 was identified as an oncogene overexpressed in human sarcoma, and these seminal papers explain the gene's importance in human cancer. MDM2 is shown to bind p53 and target it for ubiquination and degradation. Thus, post-translational regulation of p53 levels is shown to be critical in attenuating the potent apoptotic and growth-arrest-inducing properties of p53.
37. Sherr CJ Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991.
38. Quelle DE, Cheng M, Ashmun RA, Sherr CJ Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA. 94:1997;669-673. A study of various murine ARF mutations which are similar to mutations found in human tumors. Most of these mutants, suprisingly, retain ARF function.
39. •].
40. •].
41. •].
42. •].
43. •] published in rapid succession demonstrate the role of various oncogenic stimuli in inducing p53 stabilization and function by increasing ARF expression.
44. Morgenbesser SD, Williams BO, Jacks T, DePinho RA p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 371:1994;72-74.
45. Askew DS, Ashmun RA, Simmons BC, Cleveland JL Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 6:1991;1915-1922.
46. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128.
47. Lowe SW, Ruley HE Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7:1993;535-545.
48. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA. 89:1992;7742-7746.
49. Qin XQ, Livingston DM, Kaelin WGJ, Adams PD Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA. 91:1994;10918-10922.
50. Shan B, Lee WH Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol. 14:1994;8166-8173.
51. Wu X, Levine AJ p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA. 91:1994;3602-3606.
52. Land H, Parada LF, Weinberg RA Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 304:1983;596-602.
53. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA Role of the INK4a locus in tumor suppression and cell mortality. Cell. 85:1996;27-37.
54. Donehower LA Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
55. Jacks T Tumor spectrum analysis in p53-mutant mice. Curr Biol. 4:1994;1-7.
56. Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castaneda V, Lianes P, Latres Eet al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol. 146:1995;1199-1206.
57. Heinzel PA, Balaram P, Bernard HU Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer. 68:1996;420-423.
58. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, Windhager R, Gadner H Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene. 15:1997;2225-2232.
59. Newcomb EW, Rao LS, Giknavorian SS, Lee SY Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia. Mol Carcinogen. 14:1995;141-146.
60. Olshan AF, Weissler MC, Pei H, Conway K, Anderson S, Fried DB, Yarbrough WG Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene. 14:1997;811-818.
61. Patino-Garcia A, Sierrasesumaga L Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet Cytogenet. 98:1997;50-55.
62. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57:1997;1731-1734.
63. Sorlie T, Martel-Planche G, Hainaut P, Lewalter J, Holm R, Borresen-Dale AL, Montesano R Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines. Br J Cancer. 77:1998;1573-1579.
64. Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer. 78:1996;287-293.
65. Fujishita T, Mizushima Y, Kashii T, Kobayashi M Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines. Anticancer Res. 18:1998;1537-1542.
66. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 8:1994;27-32.
67. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA. 91:1994;11045-11049.
68. Glendening JM, Flores JF, Walker GJ, Stone S, Albino AP, Fountain JW Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res. 55:1995;5531-5535.
69. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet. 10:1995;351-353.
70. Whelan AJ, Bartsch D, Goodfellow PJ A familial syndrome of pancreatic cancer and melanoma in the CDKN2 tumor-suppressor gene. N Engl J Med. 333:1995;975-977.
71. INK4a mutations in the tumors of patients with multiple, sporadic (i.e. non familial) melanomas. The specific mutations identified were shown to have decreased cdk binding affinity in a biochemical analysis.
72. Haluska FG, Hodi FS Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 16:1998;670-682.
73. INK4a and pRB.
74. Lutzker SG, Levine AJ A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med. 2:1996;804-810.
75. •].
76. •].
77. •].
78. •] demonstrate the ability of p300/CBP to coactivate p53. Direct binding of p300/CBP with p53 is demonstrated. These papers suggest this coactivation may be in part through histone acetylation and alterations of chromatin structure.
79. •].
80. •] shows that p53 can be post-translationally modified by p300 and that this modification increases p53 transactivation. The second paper shows that p300 may also play a role in p53 degradation induced by MDM2.
81. Jacobs JJL, Kieboom K, Marino S, DePinho RA, van Lohuizen M The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the INK4A locus. Nature. 397:1999;164-168. This paper shows that mice deficient in bmi-1, a gene thought to be important in determining chromatin structure in mammals, have developmental defects of the lymphoid and nervous systems. Furthermore, this phenotype - as well as premature senescence in vitro of cells from these animals - can be rescued by crossing the animals onto mice with disruptions of the INK4a/ARF locus. These results imply that transcription of the INK4a/ARF locus is regulated in some tissues by the establishment of repressive chromatin structure which depends on the bmi-1 gene.